Replicate Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10210 Campus Point Dr Ste 150, San Diego...Website
www.replicatebioscience.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About Replicate Bioscience
Replicate Bioscience is at the forefront of developing innovative self-replicating RNA (srRNA) technology aimed at expanding treatment options for various diseases. Their platform utilizes srRNA vectors to enhance protein expression and therapeutic effects within cells. The company is advancing a diverse pipeline of srRNA treatments targeting infectious diseases, oncology, and autoimmune disorders. By improving upon traditional linear mRNA, Replicate aims to provide better outcomes for a larger patient population.Explore more
Replicate Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Replicate Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Replicate Bioscience
Click to see if Replicate Bioscience had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Replicate Bioscience has new funding data
Check if Replicate Bioscience has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Replicate Bioscience launches new products
Check out if Replicate Bioscience is spiking on competitors!
Earning: See what the market has to say on Replicate Bioscience recently announced quarterly report
Replicate Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Replicate Bioscience as Masked Content
Find 2 more new buyers
Compare Similar Companies to Replicate Bioscience
Compare insights from companies similar to Replicate Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Replicate Bioscience
<$5M
11-50
Private
$46M
2020
SM
Shigeki Miyake-StonerSenior Head of Technology, Scientific Director
Company Profile Activity
Activity Insights
Replicate Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Replicate Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Replicate Bioscience.
Replicate Bioscience financials insights
Gather financial insights about Replicate Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$6M
Series A
$40M
Replicate Bioscience Tech Stack
A closer look at the technologies used by Replicate Bioscience
Most Recent Scoops
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Replicate Bioscience News & Media
Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian licensing terms SAN DIEGO, Jan. 8, 2026...Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer
Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company...Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000
Eight month follow-up data published in Communications Medicine, a Nature portfolio journal Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for rabies, an ongoing global public health concern Optimized RNA vaccine demonstrates ability...Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes
Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research funding and could potentially receive up to approximately US$550 million, in addition to...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Replicate Bioscience
Sign Up For FreeTo access detailed company insights
Replicate Bioscience is at the forefront of developing innovative self-replicating RNA (srRNA) technology aimed at expanding treatment options for various diseases. Their platform utilizes srRNA vectors to enhance protein expression and therapeutic effects within cells. The company is advancing a diverse pipeline of srRNA treatments targeting infec... Read More
